RxDoctor Payments Data

Allison McClanahan, APRN

Nurse Practitioner · Paducah, KYNPI 1649726670

Payments from drug & device makers

$3,159in general payments, 2019–2025

Across 140 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$789
  • Regeneron Healthcare Solutions, Inc.$544
  • Amgen$354
  • GSK$296
  • CSL Behring$257
  • Takeda Pharmaceuticals U.S.A., Inc.$214
  • plus $706 from 15 others

What the payments were for

  • Food & beverage$2,97194%
  • Education$1886%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,159 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$79,300
Medicare patients
171
Services billed
3,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,071
Epinephrine18$4,277
Albuterol Sulfate HfaAlbuterol Sulfate37$857
Azelastine Hcl25$743
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav63$506
Fluticasone Propionate22$221
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst15$152
Doxycycline Hyclate24$112
Azithromycin23$103
Methylprednisolone15$88
Montelukast Sodium15$56
Lisinopril11$43
Prednisone29$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$296$14,07116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →